FBFabienne Briand-Mésange

Fabienne Briand-Mésange

*This is an algorithmically generated author record based on publicly available information.

Fabienne Briand-Mésange has a total of 44 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Evidence for Pro-Inflammatory Activity of LTα3 on Macrophages: Significance for Experimental Arthritis and for Therapeutic Switching in Rheumatoid Arthritis Patients

    by Ariane Benezech, Jacques-Eric Gottenberg, Yannick Degboé, Andrey Kruglov, Jane Grogan, Fabienne Briand-Mésange, Alain Cantagrel, Adeline Ruyssen-Witrand, Jean-Luc Davignon

    Lymphotoxin-alpha (LTα3) is a soluble cytokine of the TNF superfamily. Its role in inflammation and arthritis is not well known. Macrophages are important in K/BxN Serum-Transfer Arthritis (STA) and rheumatoid arthritis (RA). Anti-TNF monoclonal antibodies as well as etanercept (ETA), a soluble TNF receptor II that also neutralizes LTα3, are efficient in the treatment of RA. Objectives: To evaluate the role of LTα3 in macrophage phenotypes and in arthritis. Methods: Macrophages were cultured in the presence of recombinant LTα3, and their phenotypes were studied. The clinical effect of blocking LTα3 in STA was evaluated, as well as the effect of switching from anti-TNF monoclonal antibodies to etanercept in the “ROC” register of RA patients. Results: We showed that recombinant LTα3 was capable of directing mouse and human macrophages towards a pro-inflammatory “M1” phenotype. In K/BxN STA, ETA decreased clinical score and joint swelling. Anti-LTα3 reduced arthritis only in TNF-KO mice, indicating that the effect of LTα3 was visible in the absence of TNF. The “ROC” register indicated that switching anti-TNF mAb to ETA did not induce clinical and biological improvement in RA. Conclusion: We show a pro-inflammatory role for LTα3 in murine and human macrophages. The neutralization of both TNF and LTα3 is not beneficial in the treatment of RA.

  • Open Access

    From Classical to Alternative Pathways of 2-Arachidonoylglycerol Synthesis: AlterAGs at the Crossroad of Endocannabinoid and Lysophospholipid Signaling

    by Fabienne Briand-Mésange, Isabelle Gennero, Juliette Salles, Stéphanie Trudel, Lionel Dahan, Jérôme Ausseil, Bernard Payrastre, Jean-Pierre Salles, Hugues Chap

    2-arachidonoylglycerol (2-AG) is the most abundant endocannabinoid (EC), acting as a full agonist at both CB1 and CB2 cannabinoid receptors. It is synthesized on demand in postsynaptic membranes through the sequential action of phosphoinositide-specific phospholipase Cβ1 (PLCβ1) and diacylglycerol lipase α (DAGLα), contributing to retrograde signaling upon interaction with presynaptic CB1. However, 2-AG production might also involve various combinations of PLC and DAGL isoforms, as well as additional intracellular pathways implying other enzymes and substrates. Three other alternative pathways of 2-AG synthesis rest on the extracellular cleavage of 2-arachidonoyl-lysophospholipids by three different hydrolases: glycerophosphodiesterase 3 (GDE3), lipid phosphate phosphatases (LPPs), and two members of ecto-nucleotide pyrophosphatase/phosphodiesterases (ENPP6–7). We propose the names of AlterAG-1, -2, and -3 for three pathways sharing an ectocellular localization, allowing them to convert extracellular lysophospholipid mediators into 2-AG, thus inducing typical signaling switches between various G-protein-coupled receptors (GPCRs). This implies the critical importance of the regioisomerism of both lysophospholipid (LPLs) and 2-AG, which is the object of deep analysis within this review. The precise functional roles of AlterAGs are still poorly understood and will require gene invalidation approaches, knowing that both 2-AG and its related lysophospholipids are involved in numerous aspects of physiology and pathology, including cancer, inflammation, immune defenses, obesity, bone development, neurodegeneration, or psychiatric disorders.


  • Open Access

    Glycerophosphodiesterase 3 (GDE3) is a lysophosphatidylinositol-specific ectophospholipase C acting as an endocannabinoid signaling switch

    by Fabienne Briand-Mésange, Véronique Pons, Sophie Allart, Julien Masquelier, Gaëtan Chicanne, Nicolas Beton, Bernard Payrastre, Giulio G. Muccioli, Jérôme Ausseil, Jean-Luc Davignon, et al.


  • Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass

    by Isabelle Gennero, Sara Laurencin-Dalicieux, Françoise Conte-Auriol, Fabienne Briand-Mésange, Danielle Laurencin, Jackie Rue, Nicolas Beton, Nicole Malet, Marianne Mus, Akira Tokumura, et al.


  • Open Access

    Calcium Phosphate Bone Cements Including Sugar Surfactants: Part Two—Injectability, Adhesive Properties and Biocompatibility

    by Ariane Bercier, Stéphane Gonçalves, Helène Autefage, Fabienne Briand-Mesange, Olivier Lignon, Juliette Fitremann

    Addition of sugar surfactants, sucrose fatty acid esters and alkylpolyglucosides to a calcium phosphate cement, designed for bone reconstruction, is described. Thanks to their adsorption at the surface of the calcium phosphate particles, the sugar surfactants allowed a full injectability and brought a very good workability. Injectability was measured by monitoring force-distance curves. With some of the selected sugar surfactants adhesive properties of the cement pastes were also observed, which were measured by tack tests. Finally, some properties related to biological applications are described, including gentamicine release and osteoblast viability experiments. The whole study demonstrates that addition of these mild surfactants improved several properties of the calcium phosphate cement, without impairing function.